At the same time, a multi-omics analysis based on genomics, transcriptomics, proteomics, and phosphoproteomics was conducted on 102 samples of ICC patients, revealing an important precise molecular subtype in ICC-ALDH1high subtype, and suggesting the combination of ALDH1A1 inhibitors in the treatment of such patients.2 Here, ALDH1A1 is linked to intrahepatic cholangiocarcinoma.